Compagnie Lombard Odier S Cm A Rubius Therapeutics, Inc. Transaction History

Compagnie Lombard Odier S Cm A

  • $6.12 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 15, 2021
SELL
$22.26 - $28.43 $3.63 Million - $4.64 Million
-163,172 Closed
0 $0
Q1 2021

Apr 23, 2021
BUY
$8.02 - $32.01 $1.31 Million - $5.22 Million
163,172 New
163,172 $4.39 Million

Others Institutions Holding RUBY

# of Institutions
2
Shares Held
325
Call Options Held
0
Put Options Held
0
View Full List

About Rubius Therapeutics, Inc.

RUBY Quotes by TradingView
  • Ticker RUBY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,357,000
  • Description
  • Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...
More about RUBY
Track This Portfolio

Track Compagnie Lombard Odier S Cm A Portfolio

Follow Compagnie Lombard Odier S Cm A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

News

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email